BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

...MK-3475, lambrolizumab) Tavo, tavokinogene telseplasmid (DNA IL-12, ImmunoPulse IL-12, OMS ElectroImmunotherapy (ImmunoPulse)) Amgen Sinovac CureVac Cryopraxis...
BioCentury | Feb 8, 2019
Clinical News

Preliminary ORR 24% for Oncosec's Tavo plus Keytruda in Phase II for melanoma

...NASDAQ:ONCS), San Diego, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Tavo (ImmunoPulse IL-12, OMS ElectroImmunotherapy, DNA IL-12...
...rate Status: Preliminary Phase II data Milestone: Complete Phase II enrollment (2019) Sandi Wong DNA IL-12, ImmunoPulse IL-12, OMS ElectroImmunotherapy (ImmunoPulse) Keytruda...
BioCentury | Jan 26, 2018
Company News

Avacta, OncoSec combine technologies

...combine Avacta’s Affimer protein platform, including its PD-L1 inhibitor AVA04, with OncoSec’s gene delivery technology ImmunoPulse...
BioCentury | Jan 19, 2018
Clinical News

OncoSec reports preliminary Phase I data for ImmunoPulse IL-12 in TNBC

...in the Phase I OMS-I140 trial showing that a single cycle of intratumoral ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12...
...Phase II trial of ImmunoPulse IL-12 in combination with a PD-1 inhibitor therapy to treat TNBC. ImmunoPulse IL-12...
...for IL-12 delivered via electroporation. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12...
BioCentury | Nov 30, 2017
Clinical News

OncoSec reports data from Phase II for ImmunoPulse IL-12 and Keytruda combo

...I-102 trial in 22 melanoma patients predicted to be PD-1 non-responders showing that ImmunoPulse IL-12 (OMS ElectroImmunotherapy, DNA IL-12...
...rate of 57%. Patients received 200 mg IV Keytruda every 3 weeks and electroporation of ImmunoPulse IL-12...
...Inc. (NASDAQ:ONCS), San Diego, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: ImmunoPulse IL-12, OMS ElectroImmunotherapy, DNA IL-12...
BioCentury | May 12, 2017
Company News

OncoSec to conduct Phase II melanoma trial combining its ImmunoPulse IL-12 and Keytruda

...NASDAQ:ONCS) said it will sponsor and conduct the Phase II PISCES trial to evaluate its ImmunoPulse IL-12...
...about 48 patients with metastatic melanoma that progressed on previous treatment with an anti-PD-1 therapy. ImmunoPulse IL-12...
...Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer Julian Zhu DNA IL-12 ImmunoPulse IL-12 Keytruda MK-3475 OMS ElectroImmunotherapy pembrolizumab OncoSec...
BioCentury | Jul 25, 2016
Clinical News

OMS ElectroImmunotherapy: Preliminary Phase II data

...metastatic and unresectable SCCHN in the open-label, U.S. Phase II OMS-I130 trial showed that intratumoral ImmunoPulse IL-12...
...Conference in Salzburg. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy , ImmunoPulse IL-12 , DNA IL-12...
BioCentury | Nov 16, 2015
Clinical News

OMS ElectroImmunotherapy: Phase II started

...OncoSec began an open-label, U.S. Phase II trial to evaluate intratumoral injections of ImmunoPulse IL-12 followed by...
...to 25 patients. OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy , ImmunoPulse IL-12 , DNA IL-12...
BioCentury | Oct 5, 2015
Clinical News

OMS ElectroImmunotherapy: Additional Phase I data

...The open-label, U.S. Phase II OMS-I110 trial in 14 evaluable patients with MCC showed that ImmunoPulse IL-12...
...control rate (DCR) was 33%, including 3 partial responses and 1 case of stable disease. ImmunoPulse IL-12...
...Nov. 5, 2012). OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy , ImmunoPulse IL-12 , DNA IL-12...
BioCentury | Sep 17, 2015
Targets & Mechanisms

Bringing danger back

...& Co. Inc. to test the combination of the anti- PD-1 mAb Keytruda pembrolizumab and DNA IL-12...
Items per page:
1 - 10 of 38